KU Leuven

4 marketed ·

Quick facts

Founded	2011

D-cure · Oncology
D-cure is a therapeutic vaccine designed to stimulate the immune system to recognize and eliminate cancer cells expressing specific tumor-associated antigens.
Mepolizumab Injection [Nucala] · Immunology / Respiratory
Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the blood and tissues.
Syntocinon (Oxytocin) · Obstetrics and Gynecology
Oxytocin is a neurohypophyseal hormone that binds to oxytocin receptors to stimulate uterine contractions and milk letdown.
Tiotropium + formoterol/beclometasone · Respiratory/Pulmonology
This combination drug provides long-acting bronchodilation via tiotropium (anticholinergic) and formoterol (beta-2 agonist), plus anti-inflammatory action via beclometasone (inhaled corticosteroid) for maintenance treatment of chronic obstructive pulmonary disease and asthma.

anti TNFa monoclonal antibody - Infliximab
drugs linked with QT-prolongation
Medication use during pregnancy
sterile talc pleurodesis
Induces pleural inflammation and fibrosis to create adhesion between visceral and parietal pleura, obliterating the pleural space.

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Top marketed products include D-cure, Mepolizumab Injection [Nucala], Syntocinon (Oxytocin), Tiotropium + formoterol/beclometasone.

KU Leuven was founded in 2011.